T1	intervention 73 82	Vitamin D
T2	eligibility 510 807	premenopausal women at high risk for breast cancer [5-year risk ≥ 1.67%, lifetime risk ≥ 20%, lobular carcinoma in situ, prior stage 0-II breast cancer, hereditary breast cancer syndrome, or high MD (heterogeneously/extremely dense)], with a baseline serum 25-hydroxyvitamin D [25(OH)D] ≤ 32 ng/mL
T3	duration 841 850	12 months
T4	control 892 899	placebo
T5	outcome-Measure 926 965	change in MD from baseline to 12 months
T6	outcome-Measure 1025 1180	erial blood biomarkers [25(OH)D, 1,25-dihydroxyvitamin D (1,25(OH)D), insulin-like growth factor (IGF)-1, IGF-binding protein-3] and MD change at 24 months
T7	No-of-participants 1188 1191	208
T8	average-age 1225 1235	44.6 years
T9	ethinicity 1246 1251	white
T10	outcome 1374 1384	MD changes
T11	outcome 1430 1465	Mean MD changes at 12 and 24 months
T12	outcome 1579 1607	mean change in serum 25(OH)D
T13	outcome 1650 1655	IGF-1
